Post progression survival in glioblastoma: where are we?

被引：11

作者：

Franceschi, Enrico ^{[1
]}

Ermani, Mario ^{[2
]}

Bartolini, Stefania ^{[1
]}

Bartolotti, Marco ^{[1
]}

Poggi, Rosalba ^{[1
]}

Tallini, Giovanni ^{[3
]}

Marucci, Gianluca ^{[3
]}

Fioravanti, Antonio ^{[4
]}

Tosoni, Alicia ^{[1
]}

Agati, Raffaele ^{[5
]}

Bacci, Antonella ^{[5
]}

Pozzati, Eugenio ^{[4
]}

Morandi, Luca ^{[3
]}

Balestrini, Damiano ^{[6
]}

Ghimenton, Claudio ^{[7
]}

Crisi, Girolamo ^{[8
]}

Brandes, Alba A. ^{[1
]}

机构：

[1] Azienda USL IRCCS Inst Neurol Sci, Bellaria Maggiore Hosp, Dept Med Oncol, I-40139 Bologna, Italy

[2] Azienda Osped Univ, Neurosci Dept, Statist & Informat Unit, Padua, Italy

[3] Univ Bologna, Bellaria Hosp, Sect Pathol, Dept Biomed & NeuroMotor Sci DiBiNeM, Bologna, Italy

[4] Azienda USL IRCCS Inst Neurol Sci, Bellaria Maggiore Hosp, Dept Neurosurg, Bologna, Italy

[5] Azienda USL IRCCS Inst Neurol Sci, Bellaria Maggiore Hosp, Dept Neuroradiol, Bologna, Italy

[6] Azienda USL IRCCS Inst Neurol Sci, Bellaria Maggiore Hosp, Dept Radiotherapy, Bologna, Italy

[7] Verona Hosp, Dept Pathol, Verona, Italy

[8] Univ Hosp Parma, Dept Neuroradiol, I-43100 Parma, Italy

来源：

JOURNAL OF NEURO-ONCOLOGY | 2015年 / 121卷 / 02期

关键词：

Glioblastoma; Recurrence; End points; Progression-free survival; Post-progression survival; BEVACIZUMAB PLUS IRINOTECAN; HIGH-GRADE GLIOMAS; PHASE-II TRIAL; RECURRENT GLIOBLASTOMA; PROMOTER METHYLATION; MALIGNANT GLIOMA; END-POINT; TEMOZOLOMIDE; MULTIFORME; LOMUSTINE;

D O I：

10.1007/s11060-014-1651-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The optimal end point for phase II studies for recurrent glioblastoma (GBM) is unclear and a matter of debate. Moreover, data about post-progression survival (PPS) after the first disease progression in GBM patients treated according to EORTC 26981/22981/NCIC CE. 3 trial are limited. The aim of this study was to evaluate the PPS in GBM patients. The analysis was made with a database on 1,006 GBM patients followed prospectively between 06/2005 and 06/2010. Eligibility criteria for the study were: age >= 18 years; PS: 0-2; chemotherapy given at disease progression after RT/TMZ. 232 patients (mean age 52 years, range 18-77 years) were enrolled. The median PFS following second line chemotherapy (PFS2) was 2.5 months (95% CI 2.1-2.9) and the rate of patients free of progression at 6 months (PFS2-6 mo), was 21.6% (95% CI 16.3-26.9%). The median PPS was 8.6 months (95% CI 7.4-9.8), PPS rates were: PPS-6: 66% (95% CI 60.3-72.9%), PPS-9: 48.2% (95% CI 41.5-54.9%) and PPS-12: 31.7% (95% CI 25.2-38.2%). PPS in unselected patients treated with alkylating agents is about 8 months. PPS rates could be of interest as an end point in future studies in recurrent GBM.

引用

页码：399 / 404

页数：6

共 16 条

[11] Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial [J].

Taal, Walter ;

Oosterkamp, Hendrika M. ;

Walenkamp, Annemiek M. E. ;

Dubbink, Hendrikus J. ;

Beerepoot, Laurens V. ;

Hanse, Monique C. J. ;

Buter, Jan ;

Honkoop, Aafke H. ;

Boerman, Dolf ;

de Vos, Filip Y. F. ;

Dinjens, Winand N. M. ;

Enting, Roelien H. ;

Taphoorn, Martin J. B. ;

van den Berkmortel, Franchette W. P. J. ;

Jansen, Rob L. H. ;

Brandsma, Dieta ;

Bromberg, Jacoline E. C. ;

van Heuvel, Irene ;

Vernhout, Rene M. ;

van der Holt, Bronno ;

van den Bent, Martin J. .

LANCET ONCOLOGY, 2014, 15 (09) :943-953

[12] Bevacizumab plus irinotecan in recurrent glioblastoma multiforme [J].

Vredenburgh, James J. ;

Desjardins, Annick ;

Herndon, James E., II ;

Marcello, Jennifer ;

Reardon, David A. ;

Quinn, Jennifer A. ;

Rich, Jeremy N. ;

Sathornsumetee, Sith ;

Gururangan, Sridharan ;

Sampson, John ;

Wagner, Melissa ;

Bailey, Leighann ;

Bigner, Darell D. ;

Friedman, Allan H. ;

Friedman, Henry S. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) :4722-4729

[13] Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma [J].

Vredenburgh, James J. ;

Desjardins, Annick ;

Herndon, James E., II ;

Dowel, Jeannette M. ;

Reardon, David A. ;

Quinn, Jennifer A. ;

Rich, Jeremy N. ;

Sathornsumetee, Sith ;

Gururangan, Sridharan ;

Wagner, Melissa ;

Bigner, Darell D. ;

Friedman, Allan H. ;

Friedman, Henry S. .

CLINICAL CANCER RESEARCH, 2007, 13 (04) :1253-1259

[14] Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group [J].

Wen, Patrick Y. ;

Macdonald, David R. ;

Reardon, David A. ;

Cloughesy, Timothy F. ;

Sorensen, A. Gregory ;

Galanis, Evanthia ;

DeGroot, John ;

Wick, Wolfgang ;

Gilbert, Mark R. ;

Lassman, Andrew B. ;

Tsien, Christina ;

Mikkelsen, Tom ;

Wong, Eric T. ;

Chamberlain, Marc C. ;

Stupp, Roger ;

Lamborn, Kathleen R. ;

Vogelbaum, Michael A. ;

van den Bent, Martin J. ;

Chang, Susan M. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) :1963-1972

[15] Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma [J].

Wick, Wolfgang ;

Puduvalli, Vinay K. ;

Chamberlain, Marc C. ;

van den Bent, Martin J. ;

Carpentier, Antoine F. ;

Cher, Lawrence M. ;

Mason, Warren ;

Weller, Michael ;

Hong, Shengyan ;

Musib, Luna ;

Liepa, Astra M. ;

Thornton, Donald E. ;

Fine, Howard A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1168-1174

[16] Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials [J].

Wong, ET ;

Hess, KR ;

Gleason, MJ ;

Jaeckle, KA ;

Kyritsis, AP ;

Prados, MD ;

Levin, VA ;

Yung, WKA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2572-2578

← 1 2 →